Abo Bibliothek: Guest
Critical Reviews™ in Oncogenesis

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Immunologic Nonresponsiveness to Tumors

Volumen 9, Ausgabe 1, 1998, pp. 35-42
DOI: 10.1615/CritRevOncog.v9.i1.30
Get accessGet access

ABSTRAKT

Over the past several years it has become clear that malignant cells express a variety of tumor associated antigens, and T cells reactive to these antigens have been identified. However, the T cells are not effective in rejecting tumors. In general, T cells that are not tolerized within the thymus have the potential to be rendered tolerant by one of three mechanisms. Immune deviation occurs when regulatory T cells which share a common precursor differentiate away from the phenotype required to effect a particular immune response. Anergy induction occurs when a T cell is stimulated through its T cell receptor in the absence of costimulation. Activation-induced cell death (AICD) is apoptosis of activated T cells upon subsequent encounter with antigen. There is emerging information that some of these mechanisms can be responsible for the lack of T cell responsiveness to tumor cells. Also, tumor cells can acquire attributes that interfere with an immune response, including down-regulation of MHC molecules or other molecules involved in antigen processing; secretion of the immunosuppressive cytokine TGFβ; and expression of the apoptosis-inducing surface molecule, Fas ligand. An expansion in our understanding of how tumor cells evade a T cell mediated death will provide insight into potential strategies to improve immunotherapeutic approaches to cancer patients.

SCHLÜSSELWÖRTER: immune tolerance, tumor immunity
REFERENZIERT VON
  1. Sioud Mouldy, Hansen Mona H., Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries, European Journal of Immunology, 31, 3, 2001. Crossref

  2. Xu Yufei, Song Guoxing, The role of CD40-CD154 interaction in cell immunoregulation, Journal of Biomedical Science, 11, 4, 2004. Crossref

  3. Fauci Janelle M., Straughn J. Michael, Ferrone Soldano, Buchsbaum Donald J., A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer, Gynecologic Oncology, 127, 2, 2012. Crossref

  4. Kim Do-Yeun, Martin Carol B., Lee Soon Nam, Martin Brian K., Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle, Cancer Immunology, Immunotherapy, 54, 10, 2005. Crossref

  5. Gilligan Moira G., Knox Pauline G., Searle Peter F., Gene Therapy: Development of Immunostimulatory Treatments for Cancer, Biotechnology and Genetic Engineering Reviews, 17, 1, 2000. Crossref

  6. Kochenderfer James N., Molldrem Jeffrey J., Leukemia vaccines, Current Oncology Reports, 3, 3, 2001. Crossref

  7. Shichkin Valentin P., Moriev Roman M., Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+T Cells, The Scientific World Journal, 2014, 2014. Crossref

  8. Phua Kyle K. L., Staats Herman F., Leong Kam W., Nair Smita K., Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity, Scientific Reports, 4, 1, 2015. Crossref

  9. Anandasabapathy Niroshana, Ford Gregory S., Bloom Debra, Holness Claire, Paragas Violette, Seroogy Christine, Skrenta Heidi, Hollenhorst Marie, Fathman C.Garrison, Soares Luis, GRAIL, Immunity, 18, 4, 2003. Crossref

  10. Allison E., Colton A.D., Gorman A.D., Kurt R., Shainheit M., A mathematical model of the effector cell response to cancer, Mathematical and Computer Modelling, 39, 11-12, 2004. Crossref

  11. Kaufmann Stefan H.E., Fensterle Joachim, Hess Jürgen, The Need for a Novel Generation of Vaccines, Immunobiology, 201, 2, 1999. Crossref

  12. Battke Christina, Ruiss Romana, Welsch Ulrich, Wimberger Pauline, Lang Stephan, Jochum Simon, Zeidler Reinhard, Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC, Cancer Immunology, Immunotherapy, 60, 5, 2011. Crossref

  13. Rashid Rashid M., Lee John M., Fareed Jawed, Young M. Rita I., In vivoHeparan Sulfate Treatment Alters the Immune Response of Normal and LLC-Bearing Mice, Immunopharmacology and Immunotoxicology, 28, 1, 2006. Crossref

  14. Cao Zhu Alexander, Daniel Dylan, Hanahan Douglas, Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer, BMC Cancer, 2, 1, 2002. Crossref

  15. Herlyn Dorothee, Birebent Brigitte, Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development, Annals of Medicine, 31, 1, 1999. Crossref

  16. Ge Ning-Ling, Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines, World Journal of Gastroenterology, 9, 10, 2003. Crossref

  17. Hiltbold Elizabeth M., Vlad Anda M., Ciborowski Pawel, Watkins Simon C., Finn Olivera J., The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells, The Journal of Immunology, 165, 7, 2000. Crossref

  18. Bartsch Hella, Bartsch Christian, Mecke Dieter, The Modulation of Melatonin in Tumor-Bearing Animals: Underlying Mechanisms and Possible Significance for Prognosis, in The Pineal Gland and Cancer, 2001. Crossref

  19. Kiertscher Sylvia M., Luo Jie, Dubinett Steven M., Roth Michael D., Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells, The Journal of Immunology, 164, 3, 2000. Crossref

  20. Magner William J., Kazim A. Latif, Stewart Carleton, Romano Michelle A., Catalano Geoffrey, Grande Catherine, Keiser Nicholas, Santaniello Frank, Tomasi Thomas B., Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors, The Journal of Immunology, 165, 12, 2000. Crossref

  21. Law Che-Leung, Grewal Iqbal S., Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges, in Therapeutic Targets of the TNF Superfamily, 647, 2009. Crossref

  22. Jensen Shawn M., Meijer Sybren L., Kurt Robert A., Urba Walter J., Hu Hong-Ming, Fox Bernard A., Regression of a Mammary Adenocarcinoma in STAT6−/− Mice Is Dependent on the Presence of STAT6-Reactive T Cells , The Journal of Immunology, 170, 4, 2003. Crossref

  23. Storb Rainer F., Lucarelli Guido, McSweeney Peter A., Childs Richard W., Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors, Hematology, 2003, 1, 2003. Crossref

  24. Gutzmer Ralf, Li Wei, Sutterwala Shaheen, Lemos Maria P., Elizalde J. Ignasi, Urtishak Sandra L., Behrens Edward M., Rivers Patricia M., Schlienger Katia, Laufer Terri M., Eck Stephen L., Marks Michael S., A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells, The Journal of Immunology, 173, 2, 2004. Crossref

  25. Storb Rainer F., Lucarelli Guido, McSweeney Peter A., Childs Richard W., Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors, Hematology, 2003, 1, 2003. Crossref

  26. Ohm Joyce E., Gabrilovich Dmitry I., Sempowski Gregory D., Kisseleva Ekaterina, Parman Kelly S., Nadaf Sorena, Carbone David P., VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression, Blood, 101, 12, 2003. Crossref

  27. Lake Douglas F., Dionne Sara O., Future Strategies in Immunotherapy, in Burger's Medicinal Chemistry and Drug Discovery, 2003. Crossref

  28. Zahran Asmaa M., Shibl Azza, Rayan Amal, Mohamed Mohamed Alaa Eldeen Hassan, Osman Amira M. M., Saad Khaled, Mahmoud Khaled Hashim, Ghandour Aliaa M. A., Elsayh Khalid I., El-Badawy Omnia, Increase in polymorphonuclear myeloid-derived suppressor cells and regulatory T-cells in children with B-cell acute lymphoblastic leukemia, Scientific Reports, 11, 1, 2021. Crossref

  29. Huang Bo, Pan Ping-Ying, Li Qingsheng, Sato Alice I., Levy David E., Bromberg Jonathan, Divino Celia M., Chen Shu-Hsia, Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host, Cancer Research, 66, 2, 2006. Crossref

  30. Nadal Elisabet, Fowler Alexis, Kanfer Ed, Apperley Jane, Goldman John, Dazzi Francesco, Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions, Experimental Hematology, 32, 2, 2004. Crossref

  31. Ishikawa Eiichi, Tsuboi Koji, Saijo Kaoru, Takano Shingo, Ohno Tadao, X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions, International Journal of Radiation Oncology*Biology*Physics, 59, 5, 2004. Crossref

  32. Tong Alex W, Stone Marvin J, Prospects for CD40-directed experimental therapy of human cancer, Cancer Gene Therapy, 10, 1, 2003. Crossref

  33. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA, Young MD, Holt JK, Trown P, Hermiston TW, Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region, Gene Therapy, 8, 15, 2001. Crossref

  34. Chen C, Fang H, Han Z, Ye F, Ji T, Gong D, Li F, Zhou J, Ma D, Gao Q, Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs, Gene Therapy, 21, 11, 2014. Crossref

  35. Takahashi Yoshiyuki, Childs Richard W., Nonmyeloablative Transplantation, Clinical Cancer Research, 10, 18, 2004. Crossref

  36. Dazzi Francesco, Szydlo Richard M, Goldman John M, Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant, Experimental Hematology, 27, 10, 1999. Crossref

  37. Igney Frederik H., Krammer Peter H., Immune escape of tumors: apoptosis resistance and tumor counterattack, Journal of Leukocyte Biology, 71, 6, 2002. Crossref

  38. Ковалева О. В., Подлесная П. А., Петренко А. А., Грачев А. Н., Состав и фенотип опухолевой стромы как маркер прогноза заболевания, Malignant tumours, 12, 3s1, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain